A Phase I Study of Subcutaneous `CYT 99 007' (Interleukin-7) in Patients With Refractory Non Hematologic Malignancy.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Interleukin-7 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
- 08 Mar 2012 Biomarkers information updated
- 07 Mar 2012 Actual end date (May 2011) added as reported by ClinicalTrials.gov.
- 07 Mar 2012 Actual end date (May 2011) added as reported by ClinicalTrials.gov.